Fludarabine
Stage IIA Mycosis Fungoides/Sezary Syndrome
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversitySmall moleculePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Stage IIA Mycosis Fungoides/Sezary Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Romidepsin Northwestern University | Phase 2 | BB |
Pembrolizumab University of Michigan Rogel Cancer Center | Phase 2 | BB |
TACROLIMUS Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | B |
MOGAMULIZUMAB University of Michigan Rogel Cancer Center | Phase 2 | B |
Lacutamab Innate Pharma | Phase 2 | B |
View all 29 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →